Stockscreener 앱 받기
4.13
4.29%
0.17
시간 외 거래:
4.22
0.09
+2.18%
Camp 4 Therapeutics Corp 주식(CAMP)의 최신 뉴스
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
This Exxon Mobil Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday - Benzinga
JPMorgan upgrades CAMP4 Therapeutics stock rating on CMP-002 potential - Investing.com
CAMP4 Shareholders Approve Equity Plan Changes and Inducement Plan - TipRanks
Camp4 Therapeutics (CAMP) director awarded 28,000 stock options - Stock Titan
Camp4 Therapeutics (CAMP) grants director 28,000 stock options - Stock Titan
Camp4 Therapeutics (CAMP) director granted options on 28,000 shares at $4.34 - Stock Titan
Camp4 Therapeutics director granted 28,000 options | CAMP Insider Trading - Stock Titan
Camp4 Therapeutics (CAMP) director awarded 28,000 stock options at $4.34 strike - Stock Titan
Camp4 Therapeutics director granted 28K options | CAMP Insider Trading - Stock Titan
CAMP4 Therapeutics (NASDAQ: CAMP) updates equity plans and elects Class II directors - Stock Titan
CAMP Initiated Coverage by Chardan Capital -- Rating Set to Buy - GuruFocus
Chardan initiates CAMP4 Therapeutics stock with buy rating - Investing.com UK
Chardan initiates CAMP4 Therapeutics stock with buy rating By Investing.com - Investing.com Canada
CAMP4 Therapeutics Q1 2026 Earnings: EPS Misses Estimates by 49.4% as Pre-Revenue Biotech Faces R&D Cost PressureEPS Estimate Trend - newsline.com
Here's Why We're Not Too Worried About Camp4 Therapeutics' (NASDAQ:CAMP) Cash Burn Situation - Yahoo Finance
CAMP4 Therapeutics (CAMP) Holds Gains: Approaching Key Resistance at $4.47Bearish Pattern Stocks - newsline.com
CAMP Technical Analysis | Trend, Signals & Chart Patterns | CAMP4 THERAPEUTICS CORP (NASDAQ:CAMP) - ChartMill
CAMP4 Therapeutics (CAMP) Edges Higher Amid Continued VolatilityRisk Reward Setups - The Legal Advocate
CAMP4 Therapeutics Surges 4.5% as Biotech Sentiment Improves — CAMP Tests Key ResistanceMomentum Stock Picks - newsline.com
CAMP Q1 2026 Earnings: Wider-Than-Expected Loss Pressures Sentiment, but Stock Holds SteadyProduct Revenue Analysis - The Legal Advocate
CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Sahm
Camp4 Therapeutics Corp CEO unveils gene expression strategy with regRNA for rare disease therapy - Traders Union
Camp4 studies CMP-002 in SYNGAP1 haploinsufficient mouse model - BioWorld News
Balyasny Asset Management (CAMP) reports 2.63M shares; 4.99% warrant blocker - Stock Titan
CAMP4 Therapeutics Reports Preclinical Success of CMP-002 in Reducing Seizures for SYNGAP1-Related Disorder, Plans Phase 1/2 Trial in 2026 - Minichart
CAMP4 Highlights Preclinical Progress of SYNGAP1 Therapy - TipRanks
CAMP4 reports positive preclinical seizure data for CMP-002 - Investing.com
Camp4 Therapeutics Corp unveils new preclinical data on SYNGAP1 seizure model in Boston - Traders Union
CAMP4 Therapeutics to Present New Preclinical Data Demonstrating CMP-002 Improves Seizure Threshold and Severity in a Model of SYNGAP1-Related Disorder - The Manila Times
CAMP4 Therapeutics to Present New Preclinical Data - GlobeNewswire
Camp4 Therapeutics Corp targets capital discipline with new R and D focus - Traders Union
CAMP4 Therapeutics Corp reports results for the quarter ended March 31Earnings Summary - TradingView
Camp4 Therapeutics Corp posts Q1 2026 financial results and reveals corporate developments - Traders Union
CAMP4 Therapeutics Corporation (CAMP) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance
Rare-disease drug moves toward human trial as CAMP4 projects cash into 2028 - Stock Titan
CAMP4 Therapeutics (NASDAQ: CAMP) details Q1 2026 results and cash runway into 2028 - Stock Titan
Camp4 Therapeutics Corporation Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
CAMP4 Therapeutics (CAMP) posts Q1 2026 loss but keeps cash runway into 2028 - Stock Titan
CAMP4 Reports First Quarter 2026 Financial Results and Corporate Highlights - GlobeNewswire
CAMP4 Therapeutics Corporation (NASDAQ:CAMP) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Short Interest in CAMP4 Therapeutics Corporation (NASDAQ:CAMP) Expands By 13.1% - MarketBeat
Camp4 Therapeutics Corp engages with SYNGAP1 families to inform regRNA therapeutic progress - Traders Union
CAMP4 Therapeutics Preprints Pioneering Study on Regulatory RNA Profiling and Gene Upregulation - The Manila Times
CAMP4 maps thousands of new RNAs for gene-boosting drugs - Stock Titan
Camp4 Therapeutics shares slide after $30 million equity offering priced - MSN
CAMP4 (CAMP) details director votes, auditor ratification and equity plan - Stock Titan
[ARS] Camp4 Therapeutics Corp SEC Filing - Stock Titan
CAMP4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Sahm
CAMP4 Therapeutics Corporation (NASDAQ:CAMP) Short Interest Down 14.2% in March - MarketBeat
Three new CAMP4 hires get stock options at $4.59 a share - Stock Titan
Camp4 Therapeutics Corp boosts team engagement with employee event on the slopes - Traders Union
CAMP4 Therapeutics (NASDAQ:CAMP) Upgraded to "Strong-Buy" at Rodman & Renshaw - MarketBeat
CAMP4 (CAMP) Stock: Market Pricing (Drifts Higher) 2026-04-15Community Hot Stocks - Newser
Rodman & Renshaw initiates CAMP4 Therapeutics stock with buy rating By Investing.com - Investing.com Australia
1.27%
1.43%
자본화:
|
볼륨(24시간):